IceCure Medical Ltd(ICCM)Earnings, Financials & Key Ratios

Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cancer cryoablation in 750 patients across Brazil, led by renowned breast surgeon Dr. Vanessa Sanvido, is underway Dr. Toulsie Ramtohul of Institut Curie, a  ProSense™ user set to lead a 900-patient breast cancer cryoablation study in France, invited to key Brazilian hospitals and interventional oncology conference to share clinical expertise CAESAREA, Israel, July 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted the growing international interest in its ProSense™ system in Brazil at the Simpósio de Radiologia Intervencionista em Oncologia ("SOBRICE Onco 2026"), one of the country's leading interventional oncology congresses.

CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that on June 18, 2026, it received written notice from Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

Published in the International Journal of Surgery, globally ranked in the top three among surgery journals ,  the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients IceCure preparing for the 2026 Japanese Breast Cancer Society meeting and planned regulatory submission for breast cancer in Japan by Terumo Corporation one of the world's top 20 medical device companies CAESAREA, Israel, June 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlights a newly published peer-reviewed journal article presenting key clinical advantages of cryoablation over radiofrequency ablation ("RFA") for early-stage breast cancer, as the Company prepares to participate in the 34th Annual Meeting of the Japanese Breast Cancer Society ("JBCS"), taking place on June 25-27, 2026 in Kyoto, Japan.

CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor, for the purchase and sale of 1,833,334 ordinary shares (or ordinary share equivalents in lieu thereof), Series D Warrants to purchase up to 1,833,334 ordinary shares (the "Series D Warrants") and Series E Warrants to purchase up to 1,833,334 ordinary shares (the "Series E Warrants," and together with the Series D Warrants, the "Warrants") at a combined purchase price of $3.00 per share and accompanying Warrants in a private placement, priced at a premium to the previous Nasdaq closing price for the Company's ordinary shares.

IceCure Medical Ltd. (NASDAQ:ICCM) shares are soaring Wednesday after the company reported a 70% jump in its U.S. commercial install base for ProSense, its breast cancer cryoablation system.